2017-05-16 13:52:32 UTC

Advent of Biosimilar Products in US GI Practice

June 1, 2017

Biosimilars have become a hot topic, but are you prepared to talk to your patients about optimum use?

Biosimilars are making gains in the U.S. drug market, accounting for about 1 percent of prescriptions written and 28 percent of drug spending.

Despite this recent growth, many patients are hesitant to be switched onto biosimilars. Among patients who heard of but are not being treated with biosimilars, 47 percent worry about the safety profile of the agents and 56 percent think the lower cost of biosimilars should not come before their safety and efficacy. AGA agrees with that sentiment, which is why we recently submitted recommendations to FDA to ensure future guidance on interchangeable biosimilars keeps patients and physicians top of mind, not insurance companies. 

To best answer your patients’ questions, you need to stay up-to-date on biosimilars. Gary Lichtenstein, MD, AGAF, Brian Feagan, MD, and David Rubin, MD, AGAF, explored biosimilars during a session at DDW® 2017. You can read a session recap on the DDW Blog

Dr. Lichtenstein goes into further details in the DDW TV interview below.

As Dr. Lichtenstein mentions, AGA has convened a task force to provide education to GIs on the use of biosimilars. Stay tuned for additional information in the upcoming months.

More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.